TY - JOUR
TI - Paclitaxel and cisplatin in advanced or recurrent carcinoma of the
endometrium: Long-term results of a phase II multicenter study
AU - Dimopoulos, MA
AU - Papadimitriou, CA
AU - Georgoulias, V
AU - Moulopoulos,
AU - LA
AU - Aravantinos, G
AU - Gika, D
AU - Karpathios, S
AU - Stamatelopoulos,
AU - S
JO - Gynecologic Oncology
PY - 2000
VL - 78
TODO - 1
SP - 52-57
PB - Academic Press Inc.
SN - 0090-8258, 1095-6859
TODO - 10.1006/gyno.2000.5827
TODO - paclitaxel; cisplatin; endometrial cancer
TODO - Objectives, Both paclitaxel and cisplatin have moderate activity in
patients with metastatic or recurrent carcinoma of the endometrium, and
the combination of these two agents has shown activity in a variety of
solid tumors. We administered this combination to patients with
metastatic or recurrent carcinoma of the endometrium to evaluate its
activity and to define its toxicity.
Methods, Twenty-four consecutive patients were treated on an outpatient
basis with paclitaxel 175 mg/m(2) administered intravenously over a 3-h
period followed by cisplatin 75 mg/m(2) administered intravenously with
granulocyte colony-stimulating factor (G-CSF) support. The chemotherapy
was repeated every 3 weeks for a maximum of six courses,
Results. Sixteen patients (67%; 95% confidence interval, 45-84%,)
achieved an objective response, including seven complete responses and
nine partial responses, The median duration of response was 7 months,
and the median times to progression and survival for all patients were
8.4 and 17.6 months, respectively, Some degree of neurotoxicity occurred
in 44% of patients. Grade 3 or 4 toxicity included granulocytopenia in
22% of patients and peripheral neuropathy in 9%.
Conclusion. The combination of paclitaxel with cisplatin with G-CSF
support appears active in patients with metastatic or recurrent
carcinoma of the endometrium, The significant incidence of neurotoxicity
is of concern and alternative methods of administration of the two
agents could be evaluated. (C) 2000 Academic Press.
ER -